Palo Alto, California – Hippocratic AI has announced the acquisition of Grove AI (https://www.grovetrials.com/). According to the company announcement Hippocratic AI is a global leader and pioneer in patient-facing generative AI healthcare agents, dedicated to bringing healthcare abundance to everyone. The company recently expanded its life sciences business through the acquisition of Grove AI, a leader in agentic AI for pharma R&D and clinical trial operations, and established a dedicated Life Sciences Division. Hippocratic AI’s generative AI agents are powered by its proprietary Polaris safety architecture, ensuring high-fidelity clinical reasoning and enterprise-grade auditability. With over 150 million clinical interactions to date and $404 million in funding, the company focuses on building non-diagnostic patient-facing clinical AI agents, explicitly prohibiting their use for prescribing or diagnosing. This strategic expansion, including a collaboration with Boston Consulting Group and the formation of a Life Sciences Executive Advisory Council, positions Hippocratic AI as a category leader in deploying safe, scalable, and clinically grounded generative AI across the biopharma and medtech value chain.

To learn more about Hippocratic AI, visit https://hippocraticai.com/
Company LinkedIn Page: https://www.linkedin.com/company/hippocratic-ai-health/

Company Contact:

Hippocratic AI
167 Hamilton Avenue 3rd Floor
Palo Alto, CA 94301
917-767-2400

SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved.